Thursday, August 27, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
HEALTHCARE & FDAFDA Approves First RAS Inhibitor for Pancreatic CancertodayDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Largest Defense IT Overhaul in Years4 weeks agoDEFENSEBoeing Lands $131B F-15 Contract—Fighter Jet DominancetodayDEFENSERocket Lab Wins $266M Space Force Contract—Suborbital Launch Capability Becomes Defense Asset4 weeks agoHEALTHCARE & FDACostco Enters Medicare Advantage—Retail Disruption LoomstodayHEALTHCARE & FDACMS Overhauls Medicare Advantage Star Ratings—Big Insurers Win, Quality Metrics Tighten4 weeks agoTRADE & TARIFFSTrump's 50% Canada Tariffs Take Effect—Retailers BracetodayDEFENSERocket Lab Wins $266M Space Force Missile Defense Contract—Suborbital Launch Niche Gets Federal Validation4 weeks agoTRADE & TARIFFSU.S. Rolls Out Iran Sanctions—Oil Prices SliptodayDEFENSEPentagon Awards Oracle $7B Software Consolidation Deal—Cloud Incumbents Face Pressure, Oracle Locks in Defense Revenue4 weeks agoHEALTHCARE & FDAAbbott's Dual Glucose-Ketone Monitor Wins FDA NodyesterdayCRYPTOSEC Settles Coinbase FOIA Suit Over Missing Gensler Texts—Crypto Compliance Pressure Eases, Coinbase Stock Gains Clarity4 weeks agoHEALTHCARE & FDARegeneron's Gene Therapy Wins First GSD Type Ia ApprovalyesterdayHEALTHCARE & FDACMS Stars Redo Lifts Medicare Advantage Insurers—Rating System Overhaul Favors UnitedHealth, Humana, Anthem4 weeks agoDEFENSEStryker Lands $100M Defense Contract—Combat Vehicle BoostyesterdayDEFENSEPentagon Awards Largest F-35 Spare Parts Contract—Lockheed Locks in Sustainment Revenue4 weeks agoTRADE & TARIFFSWalmart Deploys $2.9B Tariff Refund Into Price CutsyesterdayDEFENSEHouse Passes $1.15T Defense Bill—Lockheed, Raytheon, General Dynamics Lock in Revenue4 weeks agoTRADE & TARIFFSTrump Lifts Ground Beef Tariffs—Ranchers Face Price PressureyesterdayMARKETSSEC Explores 23-Hour Stock Trading—Market Makers and Tech Platforms Get New Revenue4 weeks agoWHITE HOUSETrump Kills Affirmative Action Rules—Contractors Face Compliance Shift2 days agoENERGYPHMSA Updates Pipeline Safety Standards—Compliance Costs Hit Operators, Benefit Inspectors4 weeks agoHEALTHCARE & FDAFDA Clears Robotic Blood Draw—Phlebotomy Shortage Eases2 days agoSEARCH DEMANDCasgevy List Price: $2.2 Million4 weeks agoWHITE HOUSELabor Dept Eases Disability Hiring Rules—Contractors Save Compliance Costs2 days agoSEARCH DEMANDData Center Power Exchange4 weeks agoWHITE HOUSELabor Dept Eases Veteran Hiring Rules—Contractors Cut Compliance2 days agoTRADE & TARIFFSAmazon Gets $600M Tariff Refund—Retailers Lift Guidance on Windfall4 weeks agoTECHCHIPS Act Transforms Binghamton Into Semiconductor Hub3 days agoTECHCommerce Awards $874M in Semiconductor R&D LOIs—Chip Makers Get Federal Backing4 weeks agoTRADE & TARIFFSTrump Administration Targets Iran's Banking System With New Sanctions3 days agoHEALTHCARE & FDAFDA Revokes Petroleum-Based Food Dyes—Natural Color Makers Win4 weeks agoTECHUtah Governor Signs Quantum Computing Initiative Order3 days agoDEFENSEHouse Passes $95B Iran War Package—Defense Contractors Lock in Revenue4 weeks agoDEFENSEFAA Engine Inspection Order Lifts MRO Stocks4 days agoWHITE HOUSETrump Blocks Critical Minerals Exports—U.S. Miners Get Protected Market4 weeks agoTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earnings4 days agoHEALTHCARE & FDAHumana Exits MA Markets—600K Members Face Plan Disruption4 weeks agoHEALTHCARE & FDATrump Vaccine Spacing Order Reshapes Pharma Demand4 days agoENERGYMichigan Court Vacates Line 5 Permit—Enbridge Faces Shutdown Risk3 weeks agoTECHD-Wave Wins Canadian Quantum Funding for Annealing4 days agoTRADE & TARIFFSAmazon Pockets $600M Tariff Refund—Retail Rivals Face Margin Squeeze3 weeks agoENERGYEnbridge Wins Federal Permit for Line 5 Tunnel5 days agoHEALTHCARE & FDAHHS Boosts Hospital Payments by $2 Billion—Acute Care Operators Win3 weeks agoENERGYFederal Court Orders Enbridge Line 5 Removal5 days agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Drug Plan Insurers Face Margin Pressure3 weeks agoWHITE HOUSEFinCEN Finalizes BOI Exemption for U.S. Persons5 days agoHEALTHCARE & FDACMS Raises IRF Payments for 2027—Rehab Hospitals Get Relief3 weeks agoHEALTHCARE & FDAGAO Finds $7.6B Medicare Hospice Overpayment6 days agoTRADE & TARIFFSTrump Administration Hits $100B Tariff Refund Milestone3 weeks agoENERGYNewsom Passes Diablo Canyon Decision to Successorlast weekDEFENSERising Defense Spending Lifts Northrop Grumman Outlook3 weeks agoDEFENSERTX Lands Fresh Missile Defense Contract—Stock Undervaluedlast weekMARKETSFTC Threatens Booking Holdings Over Priceline Practices3 weeks agoTECHCommerce Eases Drone Export Rules—U.S. Makers Winlast weekHEALTHCARE & FDAFTC Sues Hims & Hers Over Privacy and Billing Practices3 weeks agoHEALTHCARE & FDAFDA Reclassifies Cancer Tests—Easier Path for Diagnosticslast weekHEALTHCARE & FDAFDA Approves Tudriqev for Advanced Melanoma3 weeks agoHEALTHCARE & FDAFTC Probes Epic Systems Over Health Records Monopolylast weekTRADE & TARIFFSRetailers Sell Off Tariff Refund Rights for Cash—Windfall Monetized Before Payout3 weeks agoDEFENSETrump's $1.5T Defense Push Fuels Colorado Contractor Windfalllast weekTECHU.S. Signs $874M Semiconductor Research LOIs—Chip Makers Get Federal Backing3 weeks agoENERGYEPA Exempts Calcium Carbonate From Pesticide Tolerance—Farm Input Easeslast weekWHITE HOUSEDHS Tightens H-1B/L-1 Visa Fees—Tech Hiring Costs Rise for Employers3 weeks agoWHITE HOUSETrump Vaccine Spacing Order Reshapes Pharma Demandlast weekENERGYMichigan Court Rejects Enbridge Line 5 Permit Under Great Lakes3 weeks agoHEALTHCARE & FDACMS Ends Medicare Part D Subsidy—Insurers Face Pressurelast weekDEFENSEPentagon Awards Space-Based Target Tracking Contracts3 weeks agoTRADE & TARIFFSTariff Refunds Flow to Retailers—Earnings Boostlast weekTECHTrump Administration Adds 6 Chipmakers to U.S. Portfolio3 weeks agoENERGYArmy Corps Permits Line 5 Tunnel—Michigan Blocks Pathlast weekWHITE HOUSEWhite House Drafts Vaccine-Autism Order—Pharma Faces Uncertainty2 weeks agoTRADE & TARIFFSTariff Refunds Turbocharge Retailer Earningslast weekDEFENSETrump Pushes $1.5T Defense Budget—Lockheed, RTX, GD Lock in Gains2 weeks agoCRYPTOSEC Delays Crypto Rules—Uncertainty Persistslast weekWHITE HOUSETrump Order Splits MMR Vaccine—Pharma Faces Demand Shift2 weeks agoTRADE & TARIFFSKimberly-Clark Pockets $45M Tariff Refundlast weekWHITE HOUSETrump Orders Childhood Vaccine Schedule Spacing2 weeks agoTRADE & TARIFFSTrump Tariffs on Drones Boost U.S. Makerslast weekHEALTHCARE & FDAFDA Updates Fresh-Cut Produce Safety Guidance2 weeks agoHEALTHCARE & FDASimparica Trio Gets Screwworm EUA—Zoetis Winslast weekENERGYNRC Approves NAC MAGNASTOR Spent Fuel Storage Cask2 weeks agoDEFENSEBlackSky Lands Multi-Year Satellite Contractlast weekHEALTHCARE & FDAFDA Clears Screwworm Prevention Drug for U.S. Livestock2 weeks agoTECHFCC Eases Broadband Label Rules—ISPs Win Flexibility2 weeks agoDEFENSEIonQ Lands $28M U.S. Defense Quantum Contract2 weeks ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Healthcare & FDA

FDA Approves First RAS Inhibitor for Pancreatic Cancer

Rasonque approval opens oncology market for targeted therapy makers.

Image: Money Racket
By at Money Racket · Aug 27, 2026

The FDA approved Rasonque (daraxonrasib), a first-in-class RAS inhibitor for metastatic pancreatic adenocarcinoma, marking the first targeted therapy to address the RAS mutations that drive most cases of the disease.

Incyte's Rasonque becomes the first proof that RAS inhibition works in pancreatic cancer—a signal that will accelerate rival pipelines and reshape oncology development.

The approval benefits oncology-focused biotech and pharma companies with existing RAS-targeting pipelines or distribution networks. Incyte (INCY), which developed Rasonque, gains a first-mover advantage in a historically underserved cancer with poor prognosis. Competitors with RAS programs—including Amgen AMGN, Genentech (part of Roche, RHHBY), and Mirati Therapeutics (MRTX)—now face a proven market signal that RAS inhibition works in pancreatic cancer, likely accelerating their own clinical timelines and label expansion strategies. Oncology-focused contract research organizations and manufacturing partners also benefit from increased demand for RAS-targeting drug development and manufacturing.

No direct losers emerge from this approval; instead, the risk is execution. Rasonque's real-world efficacy, tolerability, and reimbursement will determine whether it becomes a standard of care or a niche option. Slower-than-expected adoption would pressure Incyte's near-term revenue and dampen investor enthusiasm for the broader RAS-inhibitor class.

Watch for Rasonque's uptake in Q4 2026 and Q1 2027 earnings calls, reimbursement decisions from major insurers, and clinical trial announcements from competitors testing RAS inhibitors in other solid tumors.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://moneyracket.com/article/fda-approves-rasonque-pancreatic-cancer/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →